Years after the acute phase of the pandemic, many patients continue to live with cardiac symptoms that defy structural explanation — their hearts appear intact, yet function poorly, shadowed by inflammation and immune disruption. The Myoflame-19 trial, enrolling 279 people across multiple centers, tested whether a combination of losartan and prednisolone could quiet that inner fire and restore cardiac function. The primary measure — how well the heart's main chamber pumps — showed no meaningful improvement over placebo, a neutral result that does not close the story of post-COVID cardiac suffe
Post-COVID cardiac trial shows losartan-prednisolone combo fails primary endpoint
Persistent cardiac symptoms affect post-COVID patients, limiting physical function and quality of life despite absence of structural heart disease.